Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10581.14 | 0.9305 | 0.8550 | 0.9569 | |
| BT-20 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10581.14 | 0.8796 | 0.7490 | 0.9569 | |
| BT-20 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10581.14 | 0.6600 | 0.2956 | 0.9569 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10473.14 | 0.9226 | 0.8809 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10473.14 | 0.9270 | 0.8878 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10473.14 | 0.9627 | 0.9429 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10473.14 | 0.9533 | 0.9285 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10473.14 | 0.9084 | 0.8588 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10473.14 | 0.9255 | 0.8854 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10473.14 | 0.9639 | 0.9447 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10473.14 | 0.8776 | 0.8107 | 1.3126 | |
| CAMA-1 | HR+ | Luminal | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10473.14 | 0.9546 | 0.9304 | 1.3126 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10518.14 | 1.0329 | 1.0545 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10518.14 | 1.0132 | 1.0219 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10518.14 | 1.0097 | 1.0160 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10518.14 | 0.9832 | 0.9721 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10518.14 | 1.0608 | 1.1004 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10518.14 | 1.0124 | 1.0205 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10518.14 | 0.9843 | 0.9739 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10518.14 | 0.8636 | 0.7709 | 1.2052 | |
| HCC1187 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10518.14 | 0.8047 | 0.6700 | 1.2052 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10577.14 | 1.0222 | 1.0458 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10577.14 | 0.9888 | 0.9769 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10577.14 | 0.9772 | 0.9532 | 0.9722 | |
| HCC3153 | TNBC | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10577.14 | 0.9920 | 0.9836 | 0.9722 |